Efficacy And Market OpportunityHaduvio met the primary endpoint with statistically-significant reductions in 24-hour cough frequency across all dose groups, indicating strong efficacy.
Strategic FocusTRVI's strategic focus on IPF-CC comes front-and-center as the key value driver, with potential for specialty pricing and concentrated operational investments for commercialization.
ValuationThe stock is considered undervalued, with the IPF-CC opportunity alone being seen as a $1 billion plus opportunity for TRVI.